More Videos
SPECIAL REPORT
MOST SHARED
- Wednesday's Economic News Crunch Could Tilt Markets
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Obama Reiterates Commitment to Boost US-India Ties
- The Social Media Gaming Threat
- NBA D-League On The Rise
- Japan Export Rebound Eases Fear of New Recession
- Stifling Anger at Work Can Kill, Survey Finds
- Australia Wheat Exporters Face Challenges: GrainCorp
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Wednesday's Economic News Crunch Could Tilt Markets
- Call Me Crazy: Confessions of a Black Friday Shopper
- Starbucks Eyes China as Next Major Market
- 'Very Blah' Christmas Is Coming for UK Retailers
- US Firms Hit by Payroll Taxes at Exactly the Wrong Time
- Citi Mortgage Reveals Something the US Treasury Won't
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com Pharma Stocks |
But there's enough gloom and doom out there so, I'm going to write about a little good news for a bunch of companies in the sector.
The journal "Science" is out with its annual ranking of the best biopharma employers. And Genentech has grabbed the top position again. It had been #1 for the first five years of the survey, but fell to #2 last year, behind Boehringer Ingelheim which dropped to #4 this year. As an aside, shares of DNA were briefly halted for trading this morning. According to Dow Jones it was due to an imbalance.
Our guy on the NYSE floor, Bob Pisani, told me there was some buzz about Roche having secured the financing to do the Genentech deal, but if that were the case wouldn't you think the stock would head in the other direction? Anyway, back to the survey.
Nearly 4,000 people took it in April and May of this year (long before Roche made a play for Genentech, so you can't argue this was a Genentech get-out-the-vote-to-show-how-special-we-really-are campaign). Thirty eight percent of them worked for biotech, 34 percent for pharma, 14 percent for biopharma and the rest in "other life sciences organizations". And they're highly educated and experienced.
Seventy percent had a Ph.D., MD or both. And almost two-thirds had been working in the industry for at least a decade. Sixty-two percent picked the company they work for as the best and they scored companies on nearly two dozen "driving characteristics." This year the top six "driving characteristics" are: 1. innovative leader in the industry, 2. social responsibility, 3. employee loyalty, 4. employer respect for employees, 5. leadership moving the company in the right direction (that one broke into the top six this year) and 6. work and personal values are aligned.
Peter Gwynne, who authored the piece wrote, "For the first time a company outside the mainstream pharmaceutical and biopharmaceutical business has reached the pinnacle of top employers." That'd be Monsanto which jumped from #8 in 2007 to #2 in 2008. The rest of the top 10 are Genzyme, the aforementioned Boehringer, followed by Schering-Plough, Roche, EMD Serono, Inc., Millennium (which has been bought by Japan's Takeda), Gilead Sciences, and Eli Lilly. LLY is so proud of breaking into the top tier that it put out a press release about it. Pfizer and Bristol-Myers Squibb are the only two big pharmas that didn't crack the top 20.
Update: AstraZeneca is no longer an exception. AZN has now joined the rest of the big pharma stocks touching new lows today.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes